{"id":"xc8","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of diabetic ketoacidosis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, XC8 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly useful in the treatment of type 2 diabetes.","oneSentence":"XC8 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:41:08.234Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT06379542","phase":"PHASE3","title":"Efficacy and Safety of XC8, Film-coated Tablets, in Children With Acute Respiratory Viral Infections","status":"RECRUITING","sponsor":"Valenta Pharm JSC","startDate":"2023-12-04","conditions":"Acute Respiratory Infection","enrollment":252},{"nctId":"NCT05558462","phase":"NA","title":"Pharmacokinetics and Bioequivalence of XC8 10 mg and 40 mg Tablets in Fasted Volunteers","status":"COMPLETED","sponsor":"Valenta Pharm JSC","startDate":"2022-08-22","conditions":"Influenza, Respiratory Viral Infection","enrollment":24},{"nctId":"NCT05273619","phase":"PHASE3","title":"Efficacy and Safety of XC8, Film-coated Tablets, 40 mg in Patients With Dry Non-productive Cough Against Acute Respiratory Viral Infection","status":"COMPLETED","sponsor":"Valenta Pharm JSC","startDate":"2022-05-23","conditions":"Common Cold, Acute Respiratory Infection, Influenza, Human","enrollment":250},{"nctId":"NCT05294250","phase":"PHASE1","title":"Study of the Effect of Food Intake on the Bioavailability of XC8 10 mg Film-coated Tablets","status":"COMPLETED","sponsor":"Valenta Pharm JSC","startDate":"2022-02-01","conditions":"Healthy","enrollment":24},{"nctId":"NCT05269329","phase":"PHASE2","title":"Efficacy and Safety of XC8, Film-coated Tablets, 10 mg in Patients With Dry Non-productive Cough Against Acute Respiratory Viral Infection","status":"COMPLETED","sponsor":"Valenta Pharm JSC","startDate":"2021-04-26","conditions":"Common Cold, Acute Respiratory Infection, Influenza, Human","enrollment":160},{"nctId":"NCT04674137","phase":"PHASE2","title":"XC8 in the Treatment of Patients With the Eosinophilic Phenotype of Bronchial Asthma","status":"COMPLETED","sponsor":"Chemlmmune Therapeutics LLC","startDate":"2020-12-16","conditions":"Bronchial Asthma, Eosinophilic Asthma","enrollment":70},{"nctId":"NCT03698630","phase":"PHASE4","title":"Single Dose Oral Dexamethasone Versus Multi-dose Prednisolone in the Treatment of Acute Exacerbations of Asthma in Children","status":"COMPLETED","sponsor":"University College Dublin","startDate":"2011-07-06","conditions":"Asthma, Acute Asthma","enrollment":250},{"nctId":"NCT03450434","phase":"PHASE2","title":"XC8 in the Treatment of Patients With Bronchial Asthma","status":"COMPLETED","sponsor":"PHARMENTERPRISES LLC","startDate":"2016-09-20","conditions":"Bronchial Asthma","enrollment":120},{"nctId":"NCT03441373","phase":"PHASE2, PHASE3","title":"XC8 in the Treatment of Patients With Acute Respiratory Viral Infection","status":"COMPLETED","sponsor":"PHARMENTERPRISES LLC","startDate":"2016-02-03","conditions":"Influenza, Acute Respiratory Infection","enrollment":320},{"nctId":"NCT03441815","phase":"PHASE1","title":"XC8 Safety, Tolerability and Pharmacokinetics in Healthy Volunteers","status":"COMPLETED","sponsor":"PHARMENTERPRISES LLC","startDate":"2015-02-14","conditions":"Asthma","enrollment":28},{"nctId":"NCT02882217","phase":"PHASE1","title":"Study to Assess Pharmacokinetics, Safety, and Tolerability of XC-8","status":"COMPLETED","sponsor":"EURRUS Biotech GmbH","startDate":"2016-08","conditions":"Asthma","enrollment":32}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Histamine glutarimide"],"phase":"phase_3","status":"active","brandName":"XC8","genericName":"XC8","companyName":"Valenta Pharm JSC","companyId":"valenta-pharm-jsc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"XC8 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}